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Abstract
Background: Radiolabeled metaiodobenzylguanidine (MIBG) is sensitive and specific for detect-
ing neuroblastoma. The extent of MIBG-avid disease is assessed using Curie scores. Although
Curie scoring is prognostic in patients with high-risk neuroblastoma, there is no standardized
method to assess the response of specific sites of disease over time. The goal of this study was
to develop approaches for Curie scoring to facilitate the calculation of scores and comparison of
specific sites on serial scans.
Procedure:We designed three semiautomated methods for determining Curie scores, each with
increasing degrees of computer assistance. Method A was based on visual assessment and tally-
ing of MIBG-avid lesions. For method B, scores were tabulated from a schematic that associated
anatomic regions to MIBG-positive lesions. For method C, an anatomic mesh was used to mark
MIBG-positive lesions with automatic assignment and tallying of scores. Five imaging physicians
experienced in MIBG interpretation scored 38 scans using each method, and the feasibility and
utility of themethods were assessed using surveys.
Results: There was good reliability between methods and observers. The user-interface methods
required57 to110 seconds longer than thevisualmethod. Imagingphysicians indicated that itwas
useful that methods B and C enabled tracking of lesions. Imaging physicians preferred method B
tomethod C because of its efficiency.
Conclusions:Wedemonstrate the feasibility of semiautomated approaches for Curie score calcu-
lation. Although more time was needed for strategies B and C, the ability to track and document
individualMIBG-positive lesions over time is a strength of thesemethods.
K EYWORDS
Curie score, MIBG, neuroblastoma
Abbreviations: COG, Children's Oncology Group; EFS, event-free survival; INRC,
International Neuroblastoma Response Criteria; INRG, International Neuroblastoma Risk
Group;MIBG, metaiodobenzylguanidine; QARC, Quality Assurance ReviewCenter; SIOPEN,
International Society of Pediatric Oncology EuropeanNetwork; SPECT, single-photon
emission computed tomography
1 INTRODUCTION
Neuroblastoma is an embryonal tumor of the sympathetic nervous
system responsible for 15% of pediatric cancer deaths in the United
States.1 It displays genetic and clinical heterogeneity. Based on
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clinical and biologic variables, patients are assigned to risk groups and
treatment regimens.2 Despite excellent outcomes for some, survival
remains poor for high-risk patients despite intensive, multimodal
therapies.3–5 Survival has been shown to be superior for those who
respond to induction therapy.6–9 123I-MIBG whole-body scintigraphy
is a powerful imaging technique for detecting neuroblastoma and
evaluating treatment response.
The current standard in the Children's Oncology Group (COG) for
comparing successive 123I- MIBG scans to assess treatment response
is the Curie method,10 as detailed in a recent consensus report from
the International Neuroblastoma Risk Group (INRG) Task Force.11 The
scoring algorithm divides the body into nine skeletal sections with a
tenth soft-tissue section. The 10 sections are graded for extent of
MIBG avidity on a 0 to 3 scale: 0 = no involvement, 1 = one site,
2 = more than one site, 3 = diffuse involvement (>50% of the seg-
ment). This method is considered “semi-subjective.” The Curie score is
the sumof all 10 segments. Serial patient Curie scores are compared to
assess treatment response.
Matthay et al reported significantly worse outcomes for patients
with total Curie scores >2 following induction chemotherapy com-
pared with those with scores of ≤2.6,12 Subsequent analyses deter-
mined that Curie scores >2 after induction but not at diagnosis in
patients enrolled on a high-risk COG study were associated with sig-
nificantly worse event-free survival (EFS).7 There was no correla-
tion between Curie score at diagnosis and survival. More recently,
in an International Society of Pediatric Oncology European Net-
work (SIOPEN) high-risk study, researchers were able to validate that
patients with a Curie score of ≤2 postinduction have significantly bet-
ter EFS.13 Although the prognostic value of Curie scores has not yet
been validated in high-risk patients receiving current COG standard
treatment including tandem stem cell transplants and immunotherapy
following induction, MIBG relative scores on bone sectors have been
integrated into the recent revision of the International Neuroblastoma
Response Criteria (INRC).14 The relative bone score is the ratio of the
Curie scores at response assessment to diagnosis (without the soft-
tissue component). Resolution of MIBG activity defines a complete
response. Apartial response is defined as a reductionof 50%or greater
in MIBG bone score. Reduction by less than 50% is stable disease. Any
new lesion represents progressive disease.
Although the prognostic significance of Curie scores has been
established, the manual methods currently used to calculate total
scores do not provide mechanisms to longitudinally track specific
lesions or easily compare regions of diffuse involvement over time.
Often, only the total Curie score is provided in the MIBG report by
the imaging physician, without documentation of the specific lesions
and sites of disease. We hypothesized that by integrating a computer-
ized user interface and automation, Curie scores would be more accu-
rately quantified and documented for longitudinal review. To test this
hypothesis, we designed three semiautomated methods to calculate
Curie scores with increasing degrees of computer assistance. A survey
was administered to evaluate the imaging physicians’ opinions regard-
ing the feasibility and utility of eachmethod in clinical practice. The aim
of the study was to compare the three methods to determine: (1) the
efficiency of each method for determining Curie scores; (2) the vari-
ance ofCurie scores between readers; and (3) the feasibility of tracking
specificMIBG-positive lesions over time.
2 METHODS
2.1 Patient cohort
Patients with neuroblastoma and available MIBG scans were iden-
tified through The University of Chicago and COG. Institutional
review board approval was obtained to collect imaging and clinical
information from patients at the University of Chicago. Consents were
obtained from patients available to consent, and a waiver was granted
for patients unavailable to consent. Deidentified scans were also
obtained from the Quality Assurance Review Center (QARC) through
COG under a data use agreement with the University of Chicago.
The use of these scans was additionally given a waiver of consent.
Participating imaging physicians also signed research consents to
collect data surrounding their use of the methods and their survey
information.
2.2 MIBG semiquantitative Curie scoring
Three semiautomated mechanisms to calculate Curie scores were
designed to allow imaging physicians to view and score planar ante-
rior and posterior 24-hour MIBG scans. In each method, a computer
interface (developed in the University of Chicago's Abras system15)
allowed the imaging physician to view the images, perform windowing
and zooming of images, and determine Curie scores. To evaluate the
three methods, MIBG scans were reviewed without any accompany-
ing clinical information by five nuclear imaging physicians experienced
in interpreting MIBG scans, from four academic institutions: Univer-
sity of Chicago, St. Jude Children's Research Hospital, University of
British Columbia, and Children's Hospital of Los Angeles. Only planar
images were reviewed. Accompanying single-photon emission com-
puted tomography (SPECT) or SPECT/CT images, if performed, were
not made available.
2.3 Method A:Manual Curie scorewithin a
computer interface
Similar to traditional Curie scoring, this method simply facilitated a
sum of scores from 10 different anatomic sites, including skeletal
(craniofacial, cervical and thoracic spine, chest (ribs/sternum/clavicles/
scapula), lumbar and sacral spine, pelvis, humeri, lower arms, femurs,
and lower legs) and soft tissue. As in traditional Curie scoring, skeletal
sites were individually scored from 0 to 3 as described above. A score
of 3 was assigned for the soft-tissue region if disease occupied >50%
of the chest or abdomen. A patient's Curie score at each time pointwas
calculated as the sum of scores over all individual sites, with a maxi-
mum score of 30.
For this method, imaging physicians reviewed each set of images
and clicked on buttons to directly indicate a 0 to 3 score for each of
the nine anatomic segments (“regions”) and the soft-tissue segment
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F IGURE 1 In the interface for method A, the radiologist indicated a score of 0–3 for each of the 10 Curie regions by using the buttons in the
lower right part of the screen. See Supporting Information Figure S2 for text in the figure
(Fig. 1; Supporting Information Figure S2). This method most closely
approximates the current scoring method of subjectively evaluating
each segment and adding the scores. The interface eases this process
by allowing the imaging physician to quickly click the score for each
segment, while the overall tally ismaintained. Furthermore, in contrast
to traditional methods, the 10 individual region scores are preserved,
allowing the clinician to return later to review the contribution from
each segment.
2.4 Method B: Computer-assisted Curie scores
Inmethod B, the imaging physiciansmarked the lesion locations on the
imagesand then indicated the correspondingCurie segmentby clicking
a schematic figure. The score of each segment (0, 1, 2, or 3) was auto-
matically computed (Fig. 2; Supporting Information Figure S2). The
imaging physician could indicate a lesion in one of three ways: simple
point, line for a linear bone lesion, or a loop to show the area of a lesion.
When a line or loop was drawn, the interface collected user input on
whether the lesions belonged to a segment with >50% tumor involve-
ment. If so, the segment was automatically scored a 3 by the system.
Otherwise, one lesion marked in a segment resulted in a 1 score for
the segment, and two or more marks resulted in a 2 score. To indicate
a soft-tissue lesion, the imaging physician held down a modifier key on
the keyboardwhile drawing the lesion instead of clicking a skeletal seg-
ment on the schematic.
After drawing one or more lesions, the imaging physician indicates
the corresponding anatomic segment. The scores were then automati-
cally updated. The schematic was color coded as a visual reference for
the imaging physician to reflect the current score for each anatomic
segment (red: 3, orange: 2, yellow: 1). The system tracked the individ-
ual segment scores as well as the current total Curie score. The lesions
and contributing segments are then preserved for later review.
2.5 Method C: Computer-assisted Curie scores
In method C, the imaging physician defined a Curie anatomic segment
regionmap or “mesh” on the patient images by specifying key anatomic
points that corresponded to points shown on a skeleton schematic
(Fig. 3A and 3B; Supporting Information Figure S2), making adjust-
ments to the regionmap as necessary by dragging the intersecting han-
dles between the segments (Fig. 3C). An anterior image mesh defined
seven of the nine skeletal regions, and a smaller posterior image mesh
defined the other two skeletal regions corresponding to the spine. The
ability to manipulate the mesh is especially useful in children, as there
may not be uniformity in anatomic landmarks identified by the mesh
generation software. The imaging physician could then mark lesions
in either image (as points, lines, or loops), except that spine lesions
were required to be marked in the posterior image, while medial rib,
sternum, and pelvic lesions were required to be marked in the ante-
rior image, in order to be assigned to the proper anatomic segment.
Based on location, each lesion mark was automatically assigned to the
corresponding Curie anatomic region, and scores were adjusted by
the systemwithout requiring additional effort from the imaging physi-
cian. A key difference between the methods B and C is that in the lat-
ter, the imaging physician need not click on the schematic to assign
an anatomic segment to a lesion. Rather, the lesion's position within
the region map automatically determined its anatomic segment. The
lesions could be specified at any time during a case, before or after the
region map itself was specified, and the region map could likewise be
modified as needed.
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F IGURE 2 In method B, the radiologist clicks on lesions in the anterior or posterior images and then indicates their corresponding anatomic
segment by clicking on the schematic in the upper right portion of the screen. See Supporting Information Figure S2 for text in the figure
2.6 Comparison of the Curie scoringmethods A, B,
and C
Imaging physicians participated in three sessions, each separated by
at least two weeks to reduce recall bias. The first session involved
learning method A and then scoring all 38 scans. The second ses-
sion involved learning methods B and C and then scoring 19 scans
using method B and 19 scans using method C, reversing this for the
third session with randomization of scan order. The 19 scans were
randomized for each imaging physician, so they all read each scan
with each method, but in different sessions. Data collected included
scores for each region and the time it took to complete scoring of each
scan.
A University of Chicago analyst was physically or virtually present
(through Skype orWebEx) with the imaging physicians at each session
and provided technical guidance to assist the imaging physicians when
needed, being careful not to influence any of the clinical decisions. This
guidance included noting and helping users correct technical mistakes
inusing the interface, occasionally noting anatomic segmentomissions,
and indicating features of the interface (such as using the color-coded
schematic to see which anatomic segments have no lesions assigned)
that could help the imaging physicians use the interfaces to their full
extent. The guidance was most often needed near the beginning of a
session, and observers generally became very proficient and confident
in using the interfaces as they progressed in experience. The software
is designed to be used unaided.
2.7 Survey
An 18-question survey was administered to characterize ease-of-
use, clinical utility, and potential adoption of each of the methods
(Supporting Information Figure S1). The secure REDCap survey was
administered via e-mail to all participating imaging physicians and was
completed by all five imaging physicians.
2.8 Statistical analysis
ANOVA testing was completed by a senior statistician in Univer-
sity of Chicago's Center for Research Informatics to analyze vari-
ance between imaging physicians andmethods. Cohen kappa statistics
and weighted Fleiss’ kappa statistics were then calculated to evaluate




Thirty-four patients from the University of Chicago with available
MIBG scans were enrolled on this study. Additionally, MIBG scans
from 4 patients were obtained from QARC for analysis. All patients
had a diagnosis of neuroblastoma except for one with metastatic
paraganglioma (Supporting Information Table S1). Twenty-seven
University of Chicago patients had metastatic disease. The patients
ranged in age from 6 weeks to 22 years (median 3 years). Eleven
scans were obtained at initial diagnosis, ten during or after induction
chemotherapy, three during or prior to immunotherapy, one at end
of therapy, and nine during therapy for relapsed disease. The four
patients with scans obtained through QARC have unknown clinical
information.
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F IGURE 3 A, Inmethod C, the radiologist first indicates
key points that will define the regionmap (“mesh”). The
radiologist clicks on 9–11 points on the anterior image (in
blue) that correspond to the points shown on the skeleton
image in the upper right corner of the screen, with the left
elbow and left fingertip points being optional. B, After the
radiologist specifies the key points, the regionmap (“mesh”)
is created, which outlines the Curie anatomic segments for
this case, and the radiologist can then adjust the regionmap
if necessary bymoving the circular handles between each
anatomic segment. C, After themesh has been created, the
radiologist can draw lesions (as points, lines, or loops), and
the system automatically assigns anatomic segments and
scores based on drawn lesion locations. See Supporting
Information Figure S2 for text in the figure
4.2 Curie scoring
4.2.1 Reliability betweenmethods
We first wanted to study whether the same observer obtained similar
results usingmethods A, B, and C. All MIBG scans were scored by each
imaging physician using all three methods (Supporting Information
Table S2). Reliability between methods was assessed with Cohen
kappa coefficient, a statistic that measures interrater agreement for
categorical items. ACohenkappa greater than0.6 denotes good agree-
ment and greater than 0.8 suggests very good agreement between
methods. Scores of 0, 1, 2, and 3 in each region were considered
categorical variables as a score of 3 represents the degree to which a
region is involvedwith disease, not the number of lesions. First analysis
was performed assuming that all Curie regions are rated with similar
reliability. The kappa statistic between methods A and B was 0.869,
indicating very good agreement (Table 1). Similarly, the kappa statistic
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Total 0.869 0.847 0.861
Region 1 Craniofacial 0.887 0.877 0.909






Region 4 Lumbar and
sacral spine
0.867 0.865 0.832
Region 5 Pelvis 0.887 0.873 0.896
Region 6 Upper arms 0.865 0.858 0.803
Region 7 Lower arms
and hands
0.678 0.618 0.737
Region 8 Femurs 0.951 0.917 0.935
Region 9 Lower legs and
feet
0.908 0.888 0.932
Region 10 Soft tissue 0.721 0.623 0.689
Cohen kappa statistics are shown comparing total Curie scores and Curie
scores for each region comparing each pair of methods. All kappa scores
are higher than 0.6, indicating very good across methods.
between methods A and C was 0.847 and between methods B and
C was 0.861. To compare all three methods, Fleiss’ kappa was used,
which is a statistical measure for assessing the reliability of agreement
between a fixed number of raters when assigning categorical ratings.
Fleiss’ kappa formethods A, B, andCwas 0.702, suggesting substantial
agreement among the methods. Similar analyses were performed by
Curie region, and kappa statistics were calculated between methods
A and B (kappa range, 0.678–0.951), methods A and C (kappa range,
0.618–0.917) and methods B and C (kappa range, 0.689–0.935).
These data suggest excellent reliability across methods. The poorest
reliability existed in regions seven (the lower arms) and region ten (soft
tissue) but even these showed substantial reliability across methods.
4.3 Interobserver reliability
We then calculated the reliability among observers for each method.
Interobserver reliability was calculated using weighted Fleiss’ kappa
statistics to show consistency between the imaging physicians
(Table 2). The kappa statistic was first calculated assuming that all
Curie regions were of similar reliability and was 0.840 for method A,
0.811 for method B, and 0.804 for method C, demonstrating excellent
reliability between observers. We then evaluated by Curie region and
found kappa statistics ranging from 0.743 to 0.933 for method A, from
0.699 to 0.918 for method B, and from 0.728 to 0.901 for method C.
Overall interobserver reliability is excellent, similar to intraobserver
reliability.
4.4 Time analysis
On average, reading scans with method B took 72% longer than with
methodA.MethodC took 141% longer thanmethodA and 68% longer
than method B. For method A, the time for scoring each scan ranged







Total 0.840 0.811 0.804
Region 1 Craniofacial 0.792 0.811 0.773






Region 4 Lumbar and
sacral spine
0.773 0.789 0.787
Region 5 Pelvis 0.743 0.724 0.728
Region 6 Upper arms 0.893 0.811 0.768
Region 7 Lower arms
and hands
0.851 0.918 0.867
Region 8 Femurs 0.905 0.865 0.834
Region 9 Lower legs and
feet
0.933 0.901 0.901
Region 10 Soft tissue 0.834 0.699 0.783
Weighted Fleiss’ kappa statistics are shown comparing total Curie scores
and Curie scores for each region for eachmethod. All kappa scores are
higher than 0.6, indicating very good interobserver reliability.
from 15 seconds to 437 seconds, for method B, the time to analyze
each scan ranged from12 to737seconds, and formethodC, the time to
analyze each scan ranged from41 to693 seconds (Supporting Informa-
tion Table S3). On average, method B took 57 seconds longer per scan
than method A, and method C took 53 seconds longer than method B,
and 110 seconds longer thanmethod A.
4.5 Physician assessment of the Curie scoring
methods
All five participating imaging physicians completed the survey (Sup-
porting Information Table S4). The imaging physicians noted how
likely they would be to utilize each method (method A: 3 very likely,
1 somewhat likely, 1 unlikely; method B: 4 very likely, 1 somewhat
unlikely; method C: 2 very likely, 2 somewhat likely, 1 unlikely). The
imaging physicians indicated that their preferred method would be
somewhat or very useful for routine MIBG scan reading. The majority
specified that the data provided by the semiautomatedmethodswould
be very useful for central reviewers evaluating MIBG scans as part of
a clinical study. All of the imaging physicians agreed that it would be
valuable for the treating oncologists to have information about the
response of individual MIBG lesions. Comments provided as part of
the survey revealed concern that method C took longer than the other
methods, and the added time needed to determine the Curie score
limited its utility as a clinical tool. However, one imaging physician
commented that a semiautomatedmethod of any kindwould be better
than current practice. Another reported that these strategies could
be incorporated into practice. Four thought it was somewhat or very
important to keep a record of the lesions that contributed to the score
in each region. Three indicated that the information provided bymeth-
ods B and C regarding each of the component scores would be useful
to oncologists for response assessment and treatment decisions.
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5 DISCUSSION
In this study, we designed and tested three semiautomated methods
for evaluating Curie scores with varying degrees of computer assis-
tance.MethodAmost closelymimics current practicewith assignment
of Curie scores to each region by visual inspection, with the system
providing a running tally. Method B involves marking MIBG-avid
lesions on the scan and assigning them to Curie regions on a schematic
figure.MethodC involves creation of amesh to defineCurie regions on
the image and then the marking of MIBG-avid lesions. We showed it is
feasible to utilize a user interface and semiautomatedmethod to apply
Curie scores. Furthermore, there was consistency across providers
and methods. The intermethod and interobserver reliability is very
goodwhen evaluating both total scores and each individual region. The
imaging physicians easily learned to use each method, indicating these
methods could be broadly employed to aid in assigning Curie scores.
Currently, many imaging physicians evaluating MIBG scans provide
only a total score. Several studies have demonstrated the scores
assigned after induction therapy are prognostic of outcome of high-
risk patients treated with prior treatment regimens. Curie scores are
included in the recently published INRC response criteria and provide
important information for treatment decisions.14 Tracking specific
MIBG-positive lesions over time is likely to enhance accurate response
assessment, provide additional prognostic information, and may
ultimately lead to more informed treatment decision-making. These
semiautomated methods have the potential to standardize Curie
scoring in clinical practice. Methods B and C took 57 seconds (72%)
and 110 seconds (141%), respectively, longer to use than method A.
However, our survey results indicated that imaging physicians pre-
ferred methods B and C to method A, because these methods enabled
longitudinal tracking of lesions. The imaging physicians also noted that
a disadvantage of method C was the increased time required when
comparedwithmethods A and B.
Analysis of patients enrolled on a previous COG clinical trial
conducted from 2001 to 2006 demonstrated that Curie scores fol-
lowing induction therapy were prognostic of outcome in patients with
stage 4 high-risk neuroblastoma.7 Extremely poor outcomes were
observed for patients with MYCN nonamplified tumors with Curie
scores >2 and for patients with MYCN-amplified disease with Curie
scores >0. Decarolis and colleagues confirmed the prognostic value
of Curie scores >2 following induction and showed that a SIOPEN
MIBG score >4 following induction was also associated with inferior
outcome.8 These studies highlight the prognostic importance ofMIBG
scoring. The current manual method of determining Curie scores
limits the ability to longitudinally monitor specific lesions or regional
disease in a standardizedmanner.Wehypothesized that by integrating
computational techniques, Curie scores would be more reliably quan-
tified and specific sites of disease could be accurately assessed for
response.
These semiautomated methods represent the first step toward
making Curie scoring more consistent. Further automation may be
achieved via the process previously reported at the University of
Chicago with Tc-99m bone scans.16,17 A computer-aided diagnostic
approach was designed to identify differences in scans from multi-
ple time points using a nonlinear image warping technique. Shiraishi
et al created a computational algorithm involving image density nor-
malization and downstream processing to successfully identify new
and resolved lesions over time. This method was subsequently found
to be beneficial 84.6% of the time and has the potential to signifi-
cantly aid in the evaluation of Tc-99 bone scans. Although bone scans
are no longer used in patients with neuroblastoma, a similar approach
could be applied to MIBG scans to help identify very subtle changes
in metastatic disease patterns, thus making this modality more quanti-
tative and leading to a more precise prognostication method for chil-
dren with neuroblastoma. Future versions of the computer-assisted
methods will need to adjust for improvements in technology, including
SPECT imaging.
To bring thesemethods to clinical practice, themethodmust be val-
idated in a larger study by comparing scores obtained using semiauto-
mated scoring to scores given by consensus review of expert readers.
A prospective study can be used to determine the feasibility of using
a semiautomatedmethod in regular clinical practice. Ultimately, broad
utilization of these methods could help to standardize the application
of Curie scores and aid in monitoring the response of MIBG-avid neu-
roblastoma over time.
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